Ind-Swift labs n: lndiaRF to acquire API, CRAMS business of Ind-Swift Labs

IndiaRF will acquire the active pharmaceutical ingredients (API) and contract research and manufacturing services (CRAMS) business of Ind-Swift Labs for a consideration of Rs 1,650 crore. ET first reported on this transaction on July 21 this year. The acquisition will be done through Synthimed Labs, a portfolio company of India Resurgence Fund

Related Keywords

Jammu ,Jammu And Kashmir ,India ,Kozhikode ,Kerala ,Shantanu Nalavadi ,India Resurgence Fund ,Indian School Of Business ,Healthcare Management Analytics Programme ,Piramal Enterprises ,Offering College ,Bain Capital ,Ind Swift Labs ,Healthcare Expertise ,Swift Labs ,Synthimed Labs ,India Resurgence ,Managing Director ,Resurgence Fund ,Piramal Enterprises Limited ,Ind Swift Labs N ,Indiarf ,Scrams ,Drugs Controller General Of India ,